Showing results (41-50 of 492) with videos related to
Sort By:
Pageof 50
Seminars in Oncology|January 8, 2017
A look backward and forward in the regulatory and treatment history of multiple myeloma: Approval of novel-novel agents, new drug development, and longer patient survivalDickran Kazandjian, Ola LandgrenAdvances in Therapy|June 16, 2023
Bispecific Monoclonal Antibodies in Multiple Myeloma: Data from ASH 2022: A PodcastOla Landgren, Omar NadeemBone Marrow Transplantation|May 6, 2018
Combination therapy with carfilzomib, lenalidomide and dexamethasone (KRd) results in an unprecedented purity of the stem cell graft in newly diagnosed patients with myelomaNishant Tageja, Neha Korde, Dickran Kazandjian, et al.Leukemia & Lymphoma|January 8, 2013
Challenges and opportunities of novel imaging techniques in monoclonal plasma cell disorders: imaging "early myeloma"Jens Hillengass, Ola LandgrenBlood Cancer Discovery|September 1, 2023
MRD and Plasma Cell Dynamics after CAR T-cell Therapy in MyelomaOla Landgren, Dickran KazandjianHematology. American Society of Hematology. Education Program|December 4, 2020
Future of CAR T cells in multiple myelomaKitsada Wudhikarn, Sham Mailankody, Eric L SmithNature Reviews. Clinical Oncology|March 15, 2017
The high price of anticancer drugs: origins, implications, barriers, solutionsVinay Prasad, Kevin De Jesús, Sham MailankodyHematology/Oncology Clinics of North America|June 17, 2023
The Role of Chimeric Antigen Receptor T-Cell Therapy in the Era of Bispecific AntibodiesKarthik Nath, Sham Mailankody, Saad Z UsmaniCytometry. Part B, Clinical Cytometry|July 7, 2015
Better therapy requires better response evaluation: Paving the way for minimal residual disease testing for every myeloma patientOla Landgren, Roger G OwenBlood Cancer Discovery|December 4, 2024
Minimal Residual Disease as an Early Endpoint for Accelerated Drug Approval in Myeloma: A RoadmapOla Landgren, Sean M DevlinPageof 50